Hookipa Pharma Inc Cash Flow Conversion Efficiency
Hookipa Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Hookipa Pharma Inc (HOOK) has a cash flow conversion efficiency ratio of -0.249x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($28.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hookipa Pharma Inc (2017–2025)
Cash flow conversion efficiency of Hookipa Pharma Inc from 2017 to 2025. This chart illustrates how Hookipa Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HOOK live share price for real-time trading data and today's change.
Hookipa Pharma Inc Cash Flow Conversion Ratio Explained
Hookipa Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hookipa Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hookipa Pharma Inc ranked by their cash flow conversion efficiency. Also see HOOK market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ecomiam SA
PA:ALECO
|
-0.357x |
|
XINYUAN REAL ESTATE ADR20
F:3XR
|
N/A |
|
High Coast Distillery AB
ST:HIGHCO-B
|
0.005x |
|
Goodyear Lastikleri TAS
IS:GOODY
|
0.150x |
|
Dubber Corporation Ltd
AU:DUB
|
-0.685x |
|
Sweden BuyersClub AB
ST:BUY
|
0.227x |
|
Invesco Asia Dragon Trust plc
LSE:IAD
|
-0.001x |
|
Regenbogen AG
F:RGB
|
0.022x |
Annual Cash Flow Conversion Efficiency for Hookipa Pharma Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hookipa Pharma Inc from 2017 to 2025. Review HOOK free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.52 Million | $-11.50 Million | -0.354x | +76.47% |
| 2024-12-31 | $51.21 Million | $-76.98 Million | -1.503x | -134.79% |
| 2023-12-31 | $89.86 Million | $-57.52 Million | -0.640x | -228.19% |
| 2022-12-31 | $102.52 Million | $-20.00 Million | -0.195x | +73.53% |
| 2021-12-31 | $89.59 Million | $-66.02 Million | -0.737x | -192.43% |
| 2020-12-31 | $156.12 Million | $-39.34 Million | -0.252x | +28.81% |
| 2019-12-31 | $117.90 Million | $-41.73 Million | -0.354x | -4.78% |
| 2018-12-31 | $44.40 Million | $-15.00 Million | -0.338x | -220.95% |
| 2017-12-31 | $-42.66 Million | $-11.91 Million | 0.279x | -- |
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more